ArticleJournal of pathogens2018
First Report of
Article in Journal of pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Bacterial Profile and Antibiotic Resistance of ESKAPEE Pathogens Isolated in Intensive Care Units from Blood Cultures: A Cross-Sectional Study from Abu Dhabi, United Arab Emirates (2018-2022).Antibiotics (Basel, Switzerland) · 2025Article
- Investigation of CTX-M Type Extended-Spectrum β-Lactamase, Carbapenem and Colistin Resistance in Enterobacterales Isolated From Dairy Cattle in Turkey.Veterinary medicine and science · 2025Article
- Molecular Surveillance of ESBL and Carbapenemase Genes in Gram-Negative Bacterial Pathogens Isolated from Various Clinical Samples Collected from Northern Region of United Arab Emirates.Microorganisms · 2025Article
- Carriage of ESBL-producing Klebsiella pneumoniae and Escherichia coli among children in rural Ghana: a cross-sectional study.Antimicrobial resistance and infection control · 2023Article
- Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producingFrontiers in antibiotics · 2023Review
- Extended Spectrum- and Carbapenemase-Based β-Lactam Resistance in the Arabian Peninsula-A Descriptive Review of Recent Years.Antibiotics (Basel, Switzerland) · 2022Review
- Antibiotics Resistance inInternational journal of microbiology · 2022Article
- Analysis of Wastewater Reveals the Spread of Diverse Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- 2003-2019: explosive spread of enterobacteria producing extended-spectrum beta-lactamases in Bangui Central African Republic.The Pan African medical journal · 2021Article
- Antibiotic-Resistance Genes inSaudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe CTX-M family of extended-spectrum beta lactamase (ESBL) enzymes is comprised of over 60
methodsForty-five non-duplicate ESBL producing isolates identified in a secondary care facility in the United Arab Emirates from June to July 2016 were studied. Gene sequencing was performed and DNA sequences were annotated using the BLAST program to identify the gene subtypes.
resultsThe majority of the ESBL positive isolates were
conclusionThe findings indicate the first description of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.